JPMorgan initiates Enanta Pharmaceuticals stock with Overweight rating. November 14, 2025
JPMorgan has initiated coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with an Overweight rating and a $17.00 price target, representing a 45% upside from the current price of $11.72. InvestingPro data shows 3 analysts have recently revised earnings upwards for the upcoming period, with the overall analyst consensus recommendation leaning toward Buy.
The firm’s positive outlook is based on recent phase 2b data for zelicapavir, an N-Protein inhibitor targeting Respiratory Syncytial Virus (RSV), which JPMorgan describes as a viral infection with significant unmet need.
The phase 2b study in high-risk adult populations demonstrated faster symptom reduction compared to placebo, ranging from approximately 0.5 to 7 days across various symptom assessments, with no major safety concerns reported.
For broader symptom measurements, including All RSV symptoms (13 symptoms) and Total RiiQ (29 symptoms), the drug showed approximately 2-7 days faster symptom resolution relative to placebo in both the overall and high-risk populations, which JPMorgan notes compares favorably to approved antivirals that typically achieve 1 day faster symptom reduction.
JPMorgan estimates potential peak worldwide sales of over $1.5 billion for zelicapavir, with more than $1 billion in the U.S. alone, assigning a 70% probability of success as Enanta focuses on partnering the asset, which could provide significant non-dilutive financing. According to InvestingPro, Enanta’s stock has surged 126% over the past six months despite not being profitable. With earnings due in just 3 days and a current ratio of 5.0, investors seeking deeper insights can access the comprehensive Pro Research Report available for this and 1,400+ other US equities. . In other recent news, Enanta Pharmaceuticals announced promising results from its clinical trials for respiratory syncytial virus (RSV) treatments. The company’s oral N-protein inhibitor, zelicapavir, demonstrated a reduction in symptom duration for pediatric patients, achieving complete symptom resolution in a median of 6.99 days compared to 8.60 days for those on placebo. Additionally, Enanta Pharmaceuticals has successfully raised $74.75 million through a public offering, selling 7,475,000 shares at $10.00 per share. This capital raise included 975,000 additional shares sold after underwriters fully exercised their option to purchase extra shares.
In related financial news, Jefferies upgraded Enanta Pharmaceuticals from Hold to Buy, raising its price target to $20.00. This upgrade reflects the potential of the company’s RSV treatments, despite mixed Phase 2b results. Furthermore, Enanta Pharmaceuticals launched another public stock offering, aiming to raise $50 million, with a provision for underwriters to purchase an additional $7.5 million in shares. This offering is subject to market conditions and regulatory approvals.
Market Data 
Markets 
AI
